دورية أكاديمية
Combination of radiation therapy-immunotherapy for head and neck cancers: Promises kept?
| العنوان: | Combination of radiation therapy-immunotherapy for head and neck cancers: Promises kept? |
|---|---|
| المؤلفون: | Huguet F; Service d'Oncologie Radiothérapie, Hôpital Tenon, 4, rue de la Chine, 75020 Paris, France. Electronic address: florence.huguet@aphp.fr., Durand B; Service d'Oncologie Radiothérapie, Hôpital Tenon, 4, rue de la Chine, 75020 Paris, France., Atallah S; Service d'Oto-Rhino-Laryngologie Chirurgie cervico-faciale, France., Prébet C; Service d'Oncologie Médicale, Hôpital Tenon, Sorbonne Université, AP-HP, Paris, France., Richard S; Service d'Oncologie Médicale, Hôpital Tenon, Sorbonne Université, AP-HP, Paris, France., Baujat B; Service d'Oto-Rhino-Laryngologie Chirurgie cervico-faciale, France. |
| المصدر: | Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique [Cancer Radiother] 2021 Dec; Vol. 25 (8), pp. 811-815. Date of Electronic Publication: 2021 Oct 26. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: France NLM ID: 9711272 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1769-6658 (Electronic) Linking ISSN: 12783218 NLM ISO Abbreviation: Cancer Radiother Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Paris : Elsevier, c1997- |
| مواضيع طبية MeSH: | Head and Neck Neoplasms/*radiotherapy , Immune Checkpoint Inhibitors/*therapeutic use , Radioimmunotherapy/*methods , Squamous Cell Carcinoma of Head and Neck/*radiotherapy, Antineoplastic Agents/therapeutic use ; Cisplatin/therapeutic use ; Humans ; Radiation Tolerance/drug effects ; Radiation-Sensitizing Agents/therapeutic use ; Randomized Controlled Trials as Topic |
| مستخلص: | Chemoradiotherapy with concurrent cisplatin has been the standard treatment for locally advanced head and neck squamous cell carcinoma (HNSCC) for over 20 years. Recently, immunotherapy, a new therapeutic class, has emerged for patients with recurrent or metastatic HNSCC and has significantly extended their survival. Will it bring the same benefit to patients with localized tumors? There is a strong rationale for combining radiation therapy and checkpoint inhibitors for HNSCC. Indeed, radiation therapy can have both immunostimulatory and immunomodulatory effects. This is what explains the famous abscopal effect. The aim of this review is to present the data available on the combination of radiation therapy and immunotherapy for HNSCC. (Copyright © 2021 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Abscopal effect; Cancers ORL; Cancers des voies aéro-digestives supérieures; Carcinome épidermoïde; Chemoradiotherapy; Chimioraiothérapie; Cisplatin; Cisplatine; Effet abscopal; Head and neck cancer; Immune checkpoint inhibitors; Immunotherapy; Immunothérapie; Inhibiteurs de checkpoint; PD1; PDL1; Radiotherapy; Radiothérapie; Squamous cell carcinoma |
| المشرفين على المادة: | 0 (Antineoplastic Agents) 0 (Immune Checkpoint Inhibitors) 0 (Radiation-Sensitizing Agents) Q20Q21Q62J (Cisplatin) |
| تواريخ الأحداث: | Date Created: 20211029 Date Completed: 20211203 Latest Revision: 20211214 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1016/j.canrad.2021.08.018 |
| PMID: | 34711485 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1769-6658 |
|---|---|
| DOI: | 10.1016/j.canrad.2021.08.018 |